^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

YL-13027

i
Other names: YL-13027, YL 13027
Associations
Company:
Shanghai YingLi Pharma
Drug class:
TGF-β1 inhibitor
Associations
24d
New P1/2 trial • Metastases
|
gemcitabine • albumin-bound paclitaxel • YL-13027
2ms
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1, N=64, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
gemcitabine • albumin-bound paclitaxel • YL-13027
10ms
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1, N=64, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jun 2024 --> Jan 2024
Enrollment open • Trial initiation date • Combination therapy • Metastases
|
gemcitabine • albumin-bound paclitaxel • YL-13027
11ms
New P1 trial • Combination therapy • Metastases
|
gemcitabine • albumin-bound paclitaxel • YL-13027
2years
Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma. (PubMed, Cell Discov)
Encouragingly, YL-13027 attenuated the growth of SBC and achieved stable disease with no serious adverse events, underscoring the clinical potential for the precision treatment of SBC with this therapy. In summary, we conducted the first single-cell RNA sequencing of SBC and identified several targets that could be translated to the treatment of SBC.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
YL-13027
over2years
YL-13027 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=54, Recruiting, Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
YL-13027
almost3years
YL-13027 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=54, Not yet recruiting, Shanghai YingLi Pharmaceutical Co. Ltd.
New P1 trial
|
PD-L1 (Programmed death ligand 1)
|
YL-13027
over3years
Clinical • P1 data • IO biomarker
|
TGFB1 (Transforming Growth Factor Beta 1)
|
TP53 mutation
|
YL-13027